CANADIAN JOURNAL OF HOSPITAL PHARMACY最新文献

{"title":"Les pharmaciens et la gérance des médicaments.","authors":"Cynthia A Jackevicius","doi":"10.4212/cjhp.3427","DOIUrl":"https://doi.org/10.4212/cjhp.3427","url":null,"abstract":"","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 1","pages":"5-6"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817226/pdf/cjhp-76-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Critical Appraisal Tools to Aid Pharmacists in Evidence-Based Practice: A Narrative Review.","authors":"Ariane Blanc, Vivian Ho, Jameason Cameron","doi":"10.4212/cjhp.3281","DOIUrl":"https://doi.org/10.4212/cjhp.3281","url":null,"abstract":"Background\u0000Pharmacists and allied health researchers need to ensure that their practice is supported by current, evidence-based information. Critical appraisal tools have been developed to aid in this process.\u0000\u0000\u0000Objectives\u0000To analyze the current landscape of critical appraisal tools and to create an aid for pharmacists and other allied health researchers to use in comparing various tools and choosing the best one for each particular study design.\u0000\u0000\u0000Data Sources\u0000A literature search of the PubMed, University of Toronto Libraries, and Cochrane Library databases was conducted in December 2021, to generate an up-to-date list of critical appraisal tools. The tools were then summarized in a descriptive table.\u0000\u0000\u0000Study Selection and Data Extraction\u0000Review articles, original manuscripts, and tool webpages were examined to develop a comparison chart based on the user-friendliness, efficiency, comprehensiveness, and reliability of each tool.\u0000\u0000\u0000Results\u0000Fourteen tools were found through the literature search. These tools were compared using the findings of included review articles, and a comparison chart was created to aid pharmacists and allied health researchers in selecting the appropriate tool for their practice.\u0000\u0000\u0000Conclusions\u0000There are many standardized critical appraisal tools that can help in assessing the quality of evidence, and the summary list of tools developed and reported here can help health care researchers to compare among them and choose the best one. No tools were found that have been specifically adapted to serve the needs of pharmacists when assessing scientific articles. Future research should examine how existing critical appraisal tools can better identify common data elements that are essential to evidence-based decision-making in pharmacy practice.","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 2","pages":"131-140"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049769/pdf/cjhp-76-131.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10131989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La pharmacie d’abord.","authors":"Christine M Bond","doi":"10.4212/cjhp.3456","DOIUrl":"https://doi.org/10.4212/cjhp.3456","url":null,"abstract":"","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 2","pages":"85-86"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049767/pdf/cjhp-76-85.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacy Students' and Pharmacist Preceptors' Perceptions of the Hospital Rotation Experience during the COVID-19 Pandemic.","authors":"Monica Lee,&nbsp;Jenny Chiu","doi":"10.4212/cjhp.3303","DOIUrl":"https://doi.org/10.4212/cjhp.3303","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic brought significant disruptions to pharmacy experiential education. To ensure the safety of students and staff, university and rotation site educators needed to make changes rapidly to adapt to the dynamic environment.</p><p><strong>Objectives: </strong>To explore the impact of the COVID-19 pandemic on pharmacy students and their preceptors during experiential rotations and to identify any barriers to learning that arose and opportunities for improvement.</p><p><strong>Methods: </strong>Two online questionnaires were developed to explore the perceptions of pharmacy students and preceptors during experiential rotations. The following topics were examined: support for rotations by the hospital and the university, perceived safety, accessibility of resources, interpersonal interactions, professional development, assessment and evaluation, and overall impressions. All Advanced Pharmacy Practice Experience students from the University of Toronto who completed 1 or more rotations at North York General Hospital during the 2020/21 academic year and their preceptors were invited to participate.</p><p><strong>Results: </strong>Sixteen and 25 questionnaires were completed by students and preceptors, respectively. Both groups agreed that they were adequately prepared for the rotations and felt safe. There was a decrease in interpersonal interactions, while the use of virtual communication tools increased. Lessons learned included the need for timely communications and access to resources for learners and preceptors, contingency plans for staff shortages and outbreaks, and workspace assessments.</p><p><strong>Conclusions: </strong>During the COVID-19 pandemic, implementation of experiential rotations was associated with many challenges, but pharmacy learners and preceptors believed the overall experience was not significantly affected.</p>","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 2","pages":"117-125"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049765/pdf/cjhp-76-117.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Side-by-Side Comparison of Methods for Environmental Monitoring for Hazardous Drug Contamination.","authors":"Chun-Yip Hon","doi":"10.4212/cjhp.3275","DOIUrl":"https://doi.org/10.4212/cjhp.3275","url":null,"abstract":"<p><strong>Background: </strong>Exposure to hazardous drugs is known to have deleterious effects on health care workers. To assess risk, environmental monitoring is conducted to ascertain drug contamination on surfaces, as dermal contact is the main route of exposure. Conventional monitoring employs wipe sampling whereby the wipe must be sent to a laboratory for analysis. This means that quantitative results are not available for some time, during which the risk remains unknown. A new device, the HD Check system, developed by BD, which uses lateral-flow immunoassay technology, allows for near real-time qualitative assessment of contamination (positive or negative); however, its sensitivity relative to the traditional method is unknown.</p><p><strong>Objective: </strong>To evaluate the ability of this novel device to detect drug contamination relative to the conventional method.</p><p><strong>Methods: </strong>Five sets of different known drug concentrations were compared between the conventional wipe sampling method and the HD Check systems for methotrexate (MTX) and cyclophosphamide (CP). Stainless steel surfaces were tested, and the drug concentrations ranged from 0 ng/cm² to twice the limit of detection (LOD) of each HD Check system.</p><p><strong>Results: </strong>For MTX, positive results were obtained in every test trial at all drug concentrations examined with the HD Check system (LOD = 0.93 ng/cm²). For CP, test results with the HD Check system (LOD = 4.65 ng/cm²) were all positive at the LOD and twice the LOD; however, at 50% and 75% of the LOD, the result was positive in only 90% (9/10) of the trials. The conventional method was able to quantify the test drug concentrations with a high level of accuracy and reproducibility.</p><p><strong>Conclusions: </strong>These results suggest the potential utility of the novel device as a screening tool for higher levels of drug contamination with MTX and CP, but additional research is needed to determine its suitability for lower concentrations, especially of CP.</p>","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 2","pages":"87-93"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049775/pdf/cjhp-76-87.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10131985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferric Derisomaltose Evaluation in Patients with Non-Dialysis-Dependent Chronic Kidney Disease or Peritoneal Dialysis.","authors":"Emma England,&nbsp;Maneka Sheffield,&nbsp;Penelope Poyah,&nbsp;David Clark,&nbsp;Jo-Anne Wilson","doi":"10.4212/cjhp.3310","DOIUrl":"https://doi.org/10.4212/cjhp.3310","url":null,"abstract":"<p><strong>Background: </strong>Iron deficiency anemia is common in patients with advanced chronic kidney disease (CKD). Ferric derisomaltose (FDI) enables iron repletion in a single dose, unlike other forms of iron for IV administration, which require multiple doses. Protocols are commonly used with other IV irons, but there are limited Canadian data for FDI, and no protocol exists.</p><p><strong>Objectives: </strong>To evaluate the efficacy and safety of FDI for patients with CKD and to ascertain information related to its use in Canadian provinces.</p><p><strong>Methods: </strong>This retrospective cohort study involved patients with non-dialysis-dependent CKD (NDD-CKD) and patients undergoing peritoneal dialysis (PD) who received FDI in a tertiary hospital in Nova Scotia between June 2020 and May 2021. Each patient was followed for a minimum of 6 months. The efficacy outcomes were the changes from baseline in hemoglobin, transferrin saturation (TSAT), and ferritin after the first dose of FDI and at 3 and 6 months. The safety outcomes were the frequency and types of adverse reactions to FDI. Electronic surveys were sent to 33 Canadian renal pharmacists to gather information about FDI use, dosing, administration, monitoring, funding, and safety in their respective organizations.</p><p><strong>Results: </strong>A total of 52 infusions were administered to 35 patients during the study period. The median times between doses 1 and 2 and between doses 2 and 3 were 19.1 and 6.6 weeks, respectively. The median change from baseline to first post-FDI follow-up blood work was significant for hemoglobin (9.0 g/L, <i>p</i> = 0.023), TSAT (11 percentage points, <i>p</i> < 0.001), and ferritin (271.4 μg/L, <i>p</i> < 0.001). Median darbepoetin doses decreased from baseline to 6 months (<i>p</i> < 0.001). Three adverse reactions occurred. At least 15 (65%) of the 23 survey respondents reported that FDI was funded by their province or was listed on their hospital drug formulary.</p><p><strong>Conclusion: </strong>This study provides evidence that FDI is an effective and safe treatment for anemia in NDD-CKD and PD patients.</p>","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"76 2","pages":"94-101"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049766/pdf/cjhp-76-94.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"« Puissiez-vous vivre à une époque intéressante » : Réduire au minimum les facteurs de l’épuisement professionnel des pharmaciens.","authors":"Glen Brown","doi":"10.4212/cjhp.3377","DOIUrl":"10.4212/cjhp.3377","url":null,"abstract":"","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"75 4","pages":"249-250"},"PeriodicalIF":0.6,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524554/pdf/cjhp-75-249.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"May You Live in Interesting Times\": Minimizing Contributors to Pharmacist Burnout.","authors":"Glen Brown","doi":"10.4212/cjhp.3350","DOIUrl":"10.4212/cjhp.3350","url":null,"abstract":"","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"75 4","pages":"247-248"},"PeriodicalIF":0.6,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524547/pdf/cjhp-75-247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9242375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating a Pharmacist-Initiated Care Bundle for Patients with Chronic Obstructive Pulmonary Disease.","authors":"Jacqueline Kwok, Michael Kammermayer, Vincent H Mabasa, Tiffany Winstone, Darwin Chan","doi":"10.4212/cjhp.3226","DOIUrl":"10.4212/cjhp.3226","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is a cause of significant morbidity and mortality, and management of patients with this complex disease remains a challenge. Pharmacists work within an interdisciplinary health care team to coordinate services and ensure that standards of care are met. A pharmacist-initiated care bundle provided in the outpatient setting has shown promising results in improving COPD management.</p><p><strong>Objective: </strong>To evaluate, in the acute care setting, the effectiveness of a pharmacist-initiated COPD care bundle in improving compliance with health care measures known to improve outcomes in patients with COPD.</p><p><strong>Methods: </strong>This retrospective chart review included patients with acute exacerbation of COPD admitted from May 14, 2019, to February 29, 2020. Completion rates for the 6 individual components of the COPD care bundle were compared between patients who did and did not receive the pharmacist-initiated intervention. A subgroup of 22 patients received the following additional interventions: documentation of the modified Medical Research Council score, assessment of COPD medications, and vaccination review and administration.</p><p><strong>Results: </strong>A total of 106 patients were included in the analysis, 53 patients in each of the control and intervention groups. The pharmacist-initiated intervention increased completion rates for the overall COPD care bundle from 2% to 17% (<i>p</i> = 0.003), for provision of the COPD flare-up action plan from 4% to 79% (<i>p</i> < 0.001), and for provision of smoking cessation education from 0% to 36% (<i>p</i> = 0.04); however, there was no significant difference in assessment by a respiratory therapist. For the subgroup that received additional interventions, vaccination reviews were conducted for 21 (96%) of the 22 patients, which led to 9 (41%) receiving a guideline-recommended vaccine.</p><p><strong>Conclusions: </strong>Pharmacist involvement in initiation of the care bundle significantly increased completion rates for the activities included in the care bundle.</p>","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"75 4","pages":"302-308"},"PeriodicalIF":0.6,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524560/pdf/cjhp-75-302.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Venous Thromboembolism and Anticoagulant Use in Patients with COVID-19 in Alberta, Canada.","authors":"Lynnea Schultz, Tammy J Bungard, Elizabeth Mackay, Pawandeep Gill, Micheal Guirguis","doi":"10.4212/cjhp.3209","DOIUrl":"10.4212/cjhp.3209","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 causes a hypercoagulable state and increases the risk of venous thromboembolism (VTE).</p><p><strong>Objectives: </strong>The primary objective was to identify VTE prevalence among patients with COVID-19 in one Canadian province. Secondary objectives were to identify the prevalence of bleeding, describe anticoagulation prescribing practices, and identify factors contributing to VTE in these patients.</p><p><strong>Methods: </strong>Adult patients admitted to Alberta hospitals between March and December 2020 with COVID-19 who had a length of stay of at least 72 hours were included in this retrospective study. VTE, bleeding events, and comorbidities were defined by <i>International Classification of Diseases and Related Health Problems, 10th Revision</i> codes. Cases of VTE and controls (no VTE) were matched on the basis of age older than 60 years, active cancer, and length of stay for the full cohort, as well as for a subgroup of patients with d-dimer data available, to assess for factors associated with VTE.</p><p><strong>Results: </strong>A total of 2544 patients were included. Median age was 66 years, 1461 patients (57.4%) were male, median weight was 77.7 kg, and median d-dimer level on admission was 1.00 mg/L. The prevalence of VTE was 3.7% (<i>n</i> = 93) and that of major and clinically relevant non-major bleeding was 4.9% (<i>n</i> = 125). Of the total population, 1224 patients (48.1%) had standard prophylactic-dose anticoagulation, 460 (18.1%) received only higher-dose anticoagulation, 248 (9.7%) received both prophylactic- and higher-dose anticoagulation, and 612 (24.1%) had no anticoagulation data. Logistic regression showed that only the presence of d-dimer above 3 mg/L was associated with a significant odds ratio for VTE (7.04, 95% confidence interval 2.43-20.84).</p><p><strong>Conclusions: </strong>VTE prevalence among patients with COVID-19 was higher than baseline prevalence in Alberta. Analysis of prescribing practices demonstrated that a large proportion of patients received higher-dose anticoagulation.</p>","PeriodicalId":51646,"journal":{"name":"CANADIAN JOURNAL OF HOSPITAL PHARMACY","volume":"75 4","pages":"286-293"},"PeriodicalIF":0.6,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524556/pdf/cjhp-75-286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9290847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}